Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study)Original paper
What was studied?
This pilot study tested whether host age affects gut microbiota recovery after antibiotics. Researchers gave mice a 10-day broad-spectrum course, then tracked recovery for six months. Mice received metronidazole and ciprofloxacin in drinking water to mimic human broad-spectrum use. Fecal pellets were collected before, during, and up to six months after treatment. Bacteria were profiled by 16S rRNA V4 sequencing, with diversity and differential abundance analyzed.
Who was studied?
The subjects were 10 female wild-type C57BL/6 mice from one colony, kept in a specific-pathogen-free facility. Five were 7 weeks old (roughly a 5-year-old child) and five were 40 weeks old (roughly middle-aged human adults). Only female mice were used to avoid sex-related confounding. The design was longitudinal, following the same animals from baseline through six months of recovery. In total, 177 fecal samples were analyzed.
What were the most important findings?
Immediately after antibiotics, taxonomic richness fell sharply in both age groups, and community composition converged to a similar depleted baseline. The Bray-Curtis index recovered within about 20 days in young mice, but older mice did not fully recover over six months. Many genera went extinct and never returned. Of 45 extinct genera in young mice, 31 (68.9%) stayed absent; of 36 in older mice, 27 (75%) stayed absent. Most lost genera belonged to the Firmicutes phylum. In older mice, Lachnospiraceae NK4A136 group became dominant during recovery.
What are the greatest implications of this study?
The results suggest older hosts recover gut microbiota more slowly and less completely after antibiotics. That could leave a persistent niche for pathobionts and raise later infection risk. This was a small pilot without an antibiotic-free control group, so conclusions are preliminary. Relative abundance shifts can also exaggerate apparent overgrowth of resistant taxa. The authors urge clinical trials of antibiotics to weigh patient age when assessing microbiota recovery and treatment effects.